Response to rituximab in B-CLL patients is adversely impacted by frequency of IL-10 competent B cells and FcγRIIIa polymorphism. A study of FCGCLL/WM and GOELAMS groups

Detalles Bibliográficos
Autores principales: Gagez, A-L, Tuaillon, E, Cezar, R, Dartigeas, C, Mahé, B, Letestu, R, Maisonneuve, H, Gouilleux-Gruart, V, Bollore, K, Ferrant, E, Aurran, T, Feugier, P, Leprêtre, S, Cartron, G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4742632/
https://www.ncbi.nlm.nih.gov/pubmed/26800078
http://dx.doi.org/10.1038/bcj.2015.115

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4742632/
https://www.ncbi.nlm.nih.gov/pubmed/26800078
http://dx.doi.org/10.1038/bcj.2015.115

Ejemplares similares